There was an upregulation in the levels of TLR4-mediated inflammatory signaling molecules in peripheral blood mononuclear cells from COVID-19 patients (Figure 1), as compared to those in the healthy controls, which may suggest an involvement of TLR4 signaling in the induction of pathological inflammation during COVID-19, suggesting that targeting TLR4-mediated inflammation may serve as a new therapeutic strategy [60]. The gene discussed is TLR4; the disease is COVID-19.